Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

By K. Papp, R. Langley, M. Lebwohl, G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M. Hsu, Yuhua Wang, Shu Li and 2 more. The Lancet, 2008

1,100 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/048328874db3bd37f1aa42cc82b4f5f11e6317b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

1. Frank O. Nestle

In Immunology

1. A. Di Cesare
2. Frank O. Nestle
3. P. Di Meglio

Citations in the corpus

• Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis (2009, positive): “…to monitor circulating levels of Th17 and Th1 cells in patients receiving ustekinumab or ABT-874, two new highly effective human mAb therapies for moderate-to-severe psoriasis that target p40 (Kimball et al., 2008; Leonardi et al., 2008; Papp et al., 2008), the subunit shared by IL-23 and IL12.”
• The IL-23/Th17 axis in the immunopathogenesis of psoriasis. (2009, background): “…multiple sclerosis; PASI, psoriasis area and severity index; RA, rheumatoid arthritis; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor to IL-23 (Belladonna et al., 2002; Parham et al., 2002; Rachitskaya et al., 2008).”